Skip to main content
. 2023 Dec 5;6(5):677–688. doi: 10.1016/j.cjco.2023.11.024

Figure 3.

Figure 3

Forest plot of (A) major adverse cardiovascular events, (B) all-cause death, (C) stent thrombosis, and (D) major bleeding with purinergic receptor type Y, subtype 12 (P2Y12) inhibitor de-escalation vs continuation of potent P2Y12 inhibitor, stratified by de-escalation strategy. CI, confidence interval; df, degrees of freedom; HOST-REDUCE-POLYTECH-ACS, Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of Reduction of Prasugrel Dose or Polymer Technology in ACS Patients; M-H, Mantel–Haenszel; TALOS-AMI, Ticagrelor Versus Clopidogrel in Stabilized Patients With Acute Myocardial Infarction; TOPIC, Timing of Platelet Inhibition After Acute Coronary Syndrome.